COMMUNIQUÉS West-GlobeNewswire

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
11/02/2026
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 into R/R AML pivotal [...]
Denovo Biopharma Announces Partnership with Orygen on Phase 2 Study Evaluating DB103 (Pomaglumetad Methionil) in Treating Psychosis
11/02/2026
SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced a partnership with Orygen to initiate a Phase 2 [...]
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET
11/02/2026
REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]
Counslr Meets School Mental Health Demands with Further National Expansion and Strategic Partnerships
11/02/2026
Text-based support Signals a Shift in School Mental Health Access NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Counslr , a leading B2B mental health and wellness platform , announced today a series of strategic [...]
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
11/02/2026
Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026 If approved, Ameluz ® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma [...]
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
11/02/2026
NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Helus Pharma nomme Michael Cola au poste de directeur général pour piloter la prochaine phase de développement et d’exécution
11/02/2026
Ancien président de la division pharmaceutique spécialisée de Shire PLC (« Shire »), il cumule plus de 30 ans d’expérience dans les domaines des neurosciences, des maladies rares et des produits pharmaceutiques [...]
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
11/02/2026
Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, [...]
Clairity Founder and CEO, Dr. Connie Lehman, Named to TIME’s 2026 TIME100 Health List
11/02/2026
A Global Leader in Breast Imaging and AI, Dr. Lehman is Advancing AI-Driven Risk Assessment to Identify Women at Elevated Risk Years Before Diagnosis TIME’s Annual List Recognizes 100 of the World’s Most Influential [...]
Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
11/02/2026
Pre-Fulfillment Prescribing Now Available in All 50 States, Supporting National Launch Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non- [...]
VIVUS Advances Patient Access with New Copay Assistance Program for PANCREAZE®
11/02/2026
— Commercially-insured patients can pay as little as $0 on their copay and up to $2,000 per fill for their PANCREAZE ® prescription CAMPBELL, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical [...]
iMDx Announces $26.0 Million Registered Direct Offering
11/02/2026
NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the “Company”), today announced that it has entered into definitive agreements with certain [...]
AIM ImmunoTech Announces Commencement of Rights Offering
11/02/2026
OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead [...]
Prenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call
11/02/2026
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today [...]
Hemp Hop Expands Bubble Hash Collection, Positions Format as Quality Benchmark
11/02/2026
CHARLOTTE, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Hemp Hop, a Charlotte-based cannabis brand founded in 2018, announced the February 2026 launch of 3 new THCa Bubble Hash products, expanding its solventless THCa [...]
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
11/02/2026
The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: [...]
Coloplast A/S - Updated Financial Calendar 2025-26
11/02/2026
Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026. The [...]
HNL Lab Medicine Opens New Patient Service Center at The Marketplace at Steamtown
11/02/2026
SCRANTON, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine is expanding access to convenient, high-quality laboratory services with the opening of a new Patient Service Center at The Marketplace at Steamtown, [...]
Psyence BioMed Announces Settlement of Shareholder Litigation
11/02/2026
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (" Psyence BioMed " or the " Company ") today announced that it has entered into a settlement agreement to resolve a direct shareholder [...]

Pages